NCT05931042View on ClinicalTrials.gov

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

CompletedOBSERVATIONAL

Enrollment

1,209

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 15, 2023

Study Completion Date

June 18, 2023

Conditions

HER2+ Breast Cancer

Interventions

DRUG

Trastuzumab

Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)

Trial Locations (1)

46000

Rawalpindi Medical University, Rawalpindi

All Listed Sponsors

lead

Rawalpindi Medical College

OTHER

NCT05931042 - Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review | Biotech Hunter | Biotech Hunter